No abstract

Four novel dimeric bis-μ-imido bridged metal-metal bonded oxidomolybdenum(V) complexes [MoOL'] (1-4) (where L' are rearranged ligands formed in situ from HL) and a new mononuclear dioxidomolybdenum(VI) complex [MoOL] (5) synthesized from salen type NO ligands are reported. This rare series of imido-bridged complexes (1-4) have been furnished from rearranged HL' ligands, containing an aromatic diimine (o-phenylenediamine) "linker", where Mo assisted hydrolysis followed by -C═N bond cleavage of one of the arms of the ligand HL took place. A monomeric molybdenum(V) intermediate species [MoO(HL')(OEt)] (I) was generated in situ. The concomitant deprotonation and dimerization of two molybdenum(V) intermediate species (I) ultimately resulted in the formation of a bis-μ-imido bridge between the two molybdenum centers of [MoOL'] (1-4). The mechanism of formation of 1-4 has been discussed, and one of the rare intermediate monomeric molybdenum(V) species I has been isolated in the solid state and characterized. The monomeric dioxidomolybdenum(VI) complex [MoOL] (5) was prepared from the ligand HL where the aromatic "linker" was replaced by an aliphatic diimine (1,2-diaminopropane). All the ligands and complexes have been characterized by elemental analysis, IR, UV-vis spectroscopy, NMR, ESI-MS, and cyclic voltammetry, and the structural features of 1, 2, 4, and 5 have been solved by X-ray crystallography. The DNA binding and cleavage activity of 1-5 have been explored. The complexes interact with CT-DNA by the groove binding mode, and the binding constants range between 10 and 10 M. Fairly good photoinduced cleavage of pUC19 supercoiled plasmid DNA was exhibited by all the complexes, with 4 showing the most promising photoinduced DNA cleavage activity of ∼93%. Moreover, in vitro cytotoxic activity of all the complexes was evaluated by MTT assay, which reveals that the complexes induce cell death in MCF-7 (human breast adenocarcinoma) and HCT-15 (colon cancer) cell lines.

No abstract

No abstract

Synthesis and characterization of mixed ligand oxidovanadium(iv) complexes [VIVO(L1–4)(LNN)] incorporating arylazo ligands: evaluation of DNA/BSA interaction and cytotoxicity activity.